Ôüìïò 16, Ôåý÷ïò 2, 2004
É. ÄñõãéáííÜêçò êáé óõí.
69. Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med, 105(Suppl):31S-8S, 1998. 70. Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol, 26:18–24, 1999. 71. Langman MJ, Jensen DM, Watson DJ, Harper SE, Xhao P-L, Quan H. Incidence of upper gastrointestinal perforations, symptomatic ulcers and bleeding (PUBS). Rofecoxib compared to NSAIDs. JAMA, 282:20:1929-33, 1999. 72. Bombardardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity in rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med, 343:1520–1528, 2000. 73. Hawkey CJ. Non-steroidal anti-inflammatory drugs and ulcersfacts and figures multiply, but do they add up? BMJ, 300:278-84, 1990. 74. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med, 115:787-96, 1991. 75. García Rodríguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet, 343:769-72, 1994. 76. Langman MJ, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet, 343:1075-8, 1994. [comment in: Lancet, 343:1051–1052, 1994]. 77. Elliott SL, Yeomans ND, Buchanan RR, Smallwood RA. Efficacy of 12 months misoprostol as prophylaxis against NSAID-induced gastric ulcers. A placebo-controlled trial. Scand J Rheumatol, 23:171-6, 1994. 78. Lanas AI, Remacha B, Esteva F, Sainz R. Risk factors associated with refractory peptic ulcers. Gastroenterology, 109:1124-33, 1995. 79. Hansen JM, Hallas J, Lauritsen JM, Bytzer P. Non-steroidal anti-inflammatory drugs and ulcer complicationsa risk factor analysis for clinical decision-making. Scand J Gastroenterol, 31:126-30, 1996. 80. Simon LS, Hatoum HT, Bittman RM, Archambault WT, Polisson RP. Risk factors for serious nonsteroidal-induced gastrointestinal complications- regression analysis of the MUCOSA trial. Fam Med, 28:204-10, 1996. 81. Perez-Gutthann S, García Rodríguez LA, Raiford DS. Individual nonsteroidal antiinflamma-
82.
83.
84.
85.
86.
87.
88.
89.
90. 91.
92.
93.
tory drugs and other risk factors for upper gastrointestinal bleeding and perforation. Epidemiology, 8:18-24, 1997. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med, 340:1888-99, 1999. Weil J, Langman MJ, Wainwright P, et al. Peptic ulcer bleedingaccessory risk factors and interactions with non-steroidal anti-inflammatory drugs. Gut, 46:27-31, 2000. Hernandez Diaz S, García Rodríguez LA. Association between non-steroidal anti-inflammatory drugs and upper gastrointestinal bleed/perforation: an overview of epidemiological studies published in the 1990s. Arch Intern Med, 2000 (in press). Bijlsma JWJ. Treatment of endoscopy-negative NSAID induced upper gastrointestinal symptoms with cimetidinean international multicentre collaborative study. Aliment Pharmacol Ther, 2S:75-83, 1988. Bijlsma JWJ. Treatment of NSAID-induced gastrointestinal lesions with cimetidinean international multicentre collaborative study. Aliment Pharmacol Ther, 2S:85-96, 1988. Van Groenendael JH, Markusse HM, Dijkmans BA, Breedveld FC. The effect of ranitidine on NSAID related dyspeptic symptoms with and without peptic ulcer disease of patients with rheumatoid arthritis and osteoarthritis. Clin Rheumatol, 15:450-6, 1996. Drossman DA, Li Z, Andruzzi E, Temple RD, Talley NJ, Thompson WG, et al. US householder survey of functional gastrointestinal disorders: prevalence, sociodemography, and health impact. Dig Dis Sci, 38:1569-80, 1993. Jones RH, Lydeard SE, Hobbs FD, Kenkre JE, Williams EI, Jones SJ, et al. Dyspepsia in England and Scotland. Gut, 31:401-5, 1990. Åëëçíéêü ºäñõìá Ãáóôñåíôåñïëïãßáò & ÄéáôñïöÞò 2002. Harris RA, Kuppermann M, Richter JE. Prevention of recurrences of erosive reflux esophagitis: a cost- effectiveness analysis of maintenance proton pump inhibition. Am J Med, 102: 78-88, 1997. Simrén M, Tack J. Functional dyspepsia: evaluation and treatment Gastroenterology Clinics North Am, 32:577-99, 2003. Arasaradnam RP, Woodward T, Parrack L, Bartlett J, Bolton RP. Audit of proton pump inhibitor (PPI) prescribing: are NICE guidelines being followed? Clin Med, 3:387-8, 2003.
79